• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.

作者信息

Bewersdorf Jan Philipp, Shimony Shai, Shallis Rory M, Liu Yiwen, Berton Guillaume, Schaefer Eva J, Zeidan Amer M, Goldberg Aaron, Stein Eytan, Marcucci Guido, Bystrom Rebecca P, Lindsley R Coleman, Chen Evan C, Ramos Jorge, Stein Anthony, Pullarkat Vinod, Aldoss Ibrahim, DeAngelo Daniel J, Neuberg Donna S, Stone Richard M, Garciaz Sylvain, Ball Brian, Stahl Maximilian

机构信息

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

出版信息

Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.

DOI:10.1002/ajh.27366
PMID:38751104
Abstract
摘要

相似文献

1
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.IDH1或IDH2突变的新诊断急性髓系白血病中，去甲基化药物与维奈托克联合治疗对比强化诱导化疗——一项多中心队列研究
Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.
2
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
3
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.老年急性髓系白血病化疗与 Venetoclax 试验（CAVEAT）：Venetoclax 联合改良强化化疗的 1b 期剂量递增研究。
J Clin Oncol. 2020 Oct 20;38(30):3506-3517. doi: 10.1200/JCO.20.00572. Epub 2020 Jul 20.
4
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and mutation: a network meta-analysis.维奈托克与艾伏尼布/恩杂鲁胺用于不适合的新诊断急性髓系白血病伴 突变患者的比较：一项网状Meta分析。
J Chemother. 2024 May;36(3):202-207. doi: 10.1080/1120009X.2023.2247200. Epub 2023 Aug 20.
5
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.维奈托克联合低甲基化药物与强化化疗治疗新诊断的伴有骨髓发育异常相关改变的急性髓系白血病：基于国际共识分类的倾向评分匹配分析
Blood Cancer J. 2024 Aug 23;14(1):144. doi: 10.1038/s41408-024-01130-7.
6
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.艾伏尼布诱导的分化增强了异柠檬酸脱氢酶2（IDH2）突变的急性髓系白血病对维奈克拉的敏感性。
Leukemia. 2022 Mar;36(3):869-872. doi: 10.1038/s41375-021-01468-y. Epub 2021 Nov 6.
7
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.
8
Single-agent and combination biologics in acute myeloid leukemia.急性髓系白血病的单药和联合生物制剂。
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):548-556. doi: 10.1182/hematology.2019000059.
9
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.NPM1 突变型 AML 中强化诱导化疗与低甲基化药物联合维奈托克的比较。
Blood Adv. 2024 Sep 24;8(18):4845-4855. doi: 10.1182/bloodadvances.2024012858.
10
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m) acute myeloid leukemia (AML).奥洛他西尼布在接受维奈托克治疗后具有突变型异柠檬酸脱氢酶 1（m）的急性髓系白血病（AML）患者中的应用。
Leuk Lymphoma. 2024 Aug;65(8):1145-1152. doi: 10.1080/10428194.2024.2333451. Epub 2024 Mar 27.

引用本文的文献

1
Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies.关于使用维奈托克联合靶向和/或免疫疗法对急性髓系白血病进行无化疗管理的综合观点。
Cell Death Discov. 2025 Aug 13;11(1):379. doi: 10.1038/s41420-025-02678-4.
2
Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis.维奈托克与去甲基化药物对比诱导化疗用于新诊断急性髓系白血病患者：一项系统评价和荟萃分析
BMC Cancer. 2025 May 19;25(1):894. doi: 10.1186/s12885-025-14311-9.
3
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management.
急性髓系白血病：2025年诊断、风险分层及管理的最新进展
Am J Hematol. 2025 May;100(5):860-891. doi: 10.1002/ajh.27625. Epub 2025 Feb 12.
4
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.用于接受维奈托克联合低甲基化药物治疗的新诊断急性髓系白血病的梅奥遗传风险模型
Am J Hematol. 2025 Feb;100(2):260-271. doi: 10.1002/ajh.27564. Epub 2024 Dec 13.
5
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.老年急性髓系白血病：从新的生物学见解到靶向治疗。
Curr Oncol. 2024 Oct 24;31(11):6632-6658. doi: 10.3390/curroncol31110490.